Actively Recruiting
Dapagliflozin in STEMI
Led by Ottawa Heart Institute Research Corporation · Updated on 2026-02-20
256
Participants Needed
1
Research Sites
149 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The goal of this clinical trial is to assess the safety and efficacy of SGLT2i in limiting infarct size in patients with STEMI referred for PPCI. Eligible STEMI patients enrolled into the trial will be randomized to a SGLT2i or placebo. Cardiovascular Magnetic Resonance (CMR) imaging will be used to determine the infarct size.
CONDITIONS
Official Title
Dapagliflozin in STEMI
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients referred for PPCI with ischemic chest discomfort lasting 30 minutes or more
- Chest pain onset within 12 hours before study entry
- ECG showing high-risk STEMI criteria: either anterior STEMI with at least 2 mm ST elevation in two or more precordial leads, or extensive non-anterior STEMI with more than 1 mm ST elevation in two or more leads plus specific additional ECG findings
You will not qualify if you...
- Age under 18 years
- Contraindications to CMR imaging
- Cardiogenic shock on presentation (Killip 4)
- Use of SGLT2 inhibitors within the last 8 weeks
- Type 1 diabetes mellitus
- Pregnancy or nursing
- Not willing to use contraception if applicable
- Chronic symptomatic heart failure with hospitalization in the past year
- Previous heart attack
- Any non-cardiovascular condition limiting life expectancy to less than one year
- Previous participation in this study
- Participation in another investigational drug or device study within 4 weeks
- Unable to provide informed consent
- Confirmed ketoacidosis at admission
- Severe liver disease (cirrhosis)
- Severe kidney impairment (eGFR below 30 mL/min/1.73m2)
- Severe valvular heart disease
- Planned coronary artery bypass graft within 90 days
- False positive STEMI diagnosis based on angiogram
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Ottawa Heart Institute
Ottawa, Ontario, Canada, K1Y 4W7
Actively Recruiting
Research Team
P
Poppy MacPhee, BScN
CONTACT
T
Tanya Abarbanel
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here